↓ Skip to main content

Dove Medical Press

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, December 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
68 Mendeley
Title
Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
Published in
Neuropsychiatric Disease and Treatment, December 2013
DOI 10.2147/ndt.s54051
Pubmed ID
Authors

Nagahide Takahashi, Masayoshi Takahashi, Takayuki Saito, Misuzu Iizumi, Yuki Saito, Hiroko Shimizu, Taka Matsumura

Abstract

This 13-week, double-blind study was conducted to confirm the efficacy and safety of paliperidone palmitate (PP), at dosing regimens approved in other countries, in Asian patients with schizophrenia.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 68 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 19%
Student > Bachelor 9 13%
Researcher 9 13%
Other 7 10%
Student > Ph. D. Student 6 9%
Other 11 16%
Unknown 13 19%
Readers by discipline Count As %
Medicine and Dentistry 21 31%
Psychology 7 10%
Neuroscience 7 10%
Nursing and Health Professions 5 7%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Other 7 10%
Unknown 16 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2013.
All research outputs
#14,183,419
of 22,733,113 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,470
of 2,977 outputs
Outputs of similar age
#176,675
of 307,131 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#25
of 53 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,977 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,131 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.